2-oxo-2-((6S,10R,13S)-6,10,13-trimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)ethyl acetate | 52212-12-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 2-oxo-2-((6S,10R,13S)-6,10,13-trimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)ethyl acetate
• 英文别名: [2-oxo-2-[(6S,10R,13S)-6,10,13-trimethyl-3-oxo-6,7,8,12,14,15-hexahydrocyclopenta[a]phenanthren-17-yl]ethyl] acetate
• CAS: 52212-12-1
• 化学式: C₂₄H₂₈O₄
• 分子量: 380.484
• InChiKey: ZTIMMGHUWULFLT-NAMXMMNJSA-N

物化性质

• 沸点：
  538.2±50.0 °C(Predicted)
• 密度：
  1.19±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  60.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  (6S,10R,13S)-17-(2-hydroxyacetyl)-6,10,13-trimethyl-3-oxo-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-17-yl acetate 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 2-oxo-2-((6S,10R,13S)-6,10,13-trimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)ethyl acetate
  参考文献：
  名称：

  NON-HORMONAL STEROID MODULATORS OF NF-KB FOR TREATMENT OF DISEASE

  摘要：

  公开号：

  EP2278978B1

文献信息

• Non-hormonal steroid modulators of NF-κβ for treatment of disease
  申请人：Reveragen Biopharma, Inc.

  公开号：US10464967B2

  公开（公告）日：2019-11-05

  The present invention relates to compounds and methods which may be useful as treatments of diseases.

  本发明涉及可能用作疾病治疗的化合物和方法。
• NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE
  申请人：Reveragen Biopharma, Inc.

  公开号：US20160375037A1

  公开（公告）日：2016-12-29

  The present invention relates to compounds and methods which may be useful as treatments of diseases.

  本发明涉及化合物和方法，可用作治疗疾病的治疗方法。
• NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE
  申请人：McCall John M.

  公开号：US20100087408A1

  公开（公告）日：2010-04-08

  The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-κB for the treatment or prevention of muscular wasting disease, including muscular dystrophy.

  本发明涉及化合物和方法，这些化合物和方法可能有用于治疗神经肌肉疾病，如肌萎缩症，并作为NF-κB的抑制剂，用于治疗或预防肌肉消耗性疾病，包括肌萎缩症。
• Non-hormonal steroid modulators of NF-κB for treatment of disease
  申请人：Validus Biopharma Inc.

  公开号：US08207151B2

  公开（公告）日：2012-06-26

  The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-κB for the treatment or prevention of muscular wasting disease, including muscular dystrophy.

  本发明涉及化合物和方法，可用作治疗神经肌肉疾病，如肌肉萎缩症，以及作为NF-κB的抑制剂，用于治疗或预防肌肉萎缩病，包括肌肉萎缩症。
• Non-hormonal steroid modulators of NF-kB for treatment of disease
  申请人：Validus Genetics

  公开号：US08673887B2

  公开（公告）日：2014-03-18

  The present invention relates to compounds and methods which may be useful for the treatment of inflammatory bowel disease, Crohn's disease and colitis.

  本发明涉及化合物和方法，可用于治疗炎症性肠病、克罗恩病和溃疡性结肠炎。